Replies to post #228879 on Avid Bioservices Inc (CDMO)

[biopharm]

Here is a paper that Freeeman published in May 2010 in Immunological Reviews.

www.ncbi.nlm.nih.gov/pmc/articles/PMC2914464/

TIM genes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity.

Freeman GJ, Casasnovas JM, Umetsu DT, DeKruyff RH.
Department of Medical Oncology, Dana-Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston, MA, USA.

Ok, looks like we have a go. Repeat ... we have a go. More than a few are all out hitting the circuits re: PS Targeting...

--------------------

Nov 19, 2015

Gordon J. Freeman: PD-1 Cancer Immunotherapy

Speaker: Gordon J. Freeman, Dana-Farber Cancer Institute, Harvard Medical Scool, Boston, USA. Host: Jonas Nilsson,
[e-mail]

Two open lectures are Offered on November 19 in collaboration between Sahlgrenska Cancer Center, Biocare and the Sahlgrenska Academy Seminars. During the lunch break between the two lectures, a light lunch is served outside the venue

Time
10: 00-11: 00
Place
Lecture Hall Arvid Carlsson, Academicum, Medicinaregatan 3

https://translate.google.com/translate?hl=en&sl=sv&u=www.akademiliv.se/seminarier/&prev=search

[biopharm]

TIM genes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity.

Freeman GJ, Casasnovas JM, Umetsu DT, DeKruyff RH.
Department of Medical Oncology, Dana-Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston, MA, USA.

Abstract
The TIM (T cell/transmembrane, immunoglobulin, and mucin) gene family plays a critical role in regulating immune responses, including allergy, asthma, transplant tolerance, autoimmunity, and the response to viral infections.
..
..

So flipped PS is everywhere..... including the affects of protein pathways re: allergies and yes... even peanut allergies for kids..

--------------------------------------------

Study: Immunotherapy Ends Peanut Allergy in Babies

At least 80 percent of babies with a peanut allergy were able to consume nuts after receiving a new immunotherapy treatment, researchers said. The study, published in the Journal of Allergy and Clinical Immunology and conducted by a team at the University of North Carolina, provided oral immunotherapy to 40 infants aged between nine and 36 months. At the end of the test, eight of 10 babies were able to consume peanuts without having an allergic reaction. The therapy itself involves giving a small dose of peanut protein daily, gradually increasing the amount given over a period of 29 weeks. The researchers then ceased feeding the child peanuts for four weeks before attempting it again. Most of the study’s participants reportedly experienced some mild side effects, but none required medical treatment. “This study provides critical evidence supporting the safety and effectiveness of peanut oral immunotherapy in treating young children newly diagnosed with peanut allergy,” said Marshall Plaut, of the National Institute of Allergy and Infectious Diseases

http://www.thedailybeast.com/cheats/2016/08/12/study-immunotherapy-ends-peanut-allergy-in-babies.html?via=desktop&source=copyurl